15 Jun - 15 Jul 2022Conversion of convertibles

RhoVac is a pharmaceutical company dedicated to immuno-oncology, signifying that the body’s own immune system is stimulated to identify and destroy cancer cells. The primary focus of RhoVac is to develop a cancer therapy that targets metastatic cells to prevent cancer recurrence and progression after primary tumour therapy. RhoVac was founded as a private company in Denmark 2007. In the following years the first steps in terms of development of the drug candidate, RV001, were taken. In 2015 the Swedish RhoVac AB, now headquarters, was founded, and in 2016 the company was listed on “Spotlight Stock Market”.

Read more on the company's website

The offer in summary